Literature DB >> 23108300

Promotion of hepatocellular carcinoma by hepatitis C virus.

Sandra Bühler1, Ralf Bartenschlager.   

Abstract

Persistent infection with the hepatitis C virus (HCV) is a major global health problem. Around 2-3% of the world's population are chronically infected, and infected individuals are at high risk of developing steatosis, fibrosis, and liver cirrhosis. The latter is a major predisposing factor for the development of hepatocellular carcinoma (HCC). It is generally accepted that an inflammatory response triggered by persistent HCV infection leads to increased cell proliferation and fibrogenesis that in turn promotes cirrhosis and ultimately HCC development. This indirect mechanism of tumor induction would explain the long incubation period from primary HCV infection to HCC and the requirement for additional cofactors such as toxins or drugs (most notably alcohol), metabolic liver diseases, steatosis, nonalcoholic liver disease, or diabetes. With the advent of adequate cell culture systems for HCV it is, however, becoming increasingly clear that the virus also contributes directly to HCC formation. Examples are the continuous induction of stress response or the massive accumulation of intracellular lipids. Moreover, viral proteins can bind to and sequester cell cycle control factors such as the retinoblastoma protein or the tumor suppressor DDX3. Thus, HCV-associated liver cancer is most likely promoted by the combined action of long-term chronic inflammation and targeted perturbations of cellular key pathways involved in metabolic homeostasis as well as cell cycle control.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23108300     DOI: 10.1159/000341688

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  15 in total

1.  Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.

Authors:  Jin-Ching Lee; Chin-Kai Tseng; Kung-Chia Young; Hung-Yu Sun; Shainn-Wei Wang; Wei-Chun Chen; Chun-Kuang Lin; Yu-Hsuan Wu
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  Hepatitis viruses exploitation of host DNA methyltransferases functions.

Authors:  Valerio Pazienza; Concetta Panebianco; Angelo Andriulli
Journal:  Clin Exp Med       Date:  2015-07-07       Impact factor: 3.984

Review 3.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

4.  Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus.

Authors:  Hui Zhang; Chun Gao; Long Fang; Shu-Kun Yao
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

5.  Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.

Authors:  Johnathan D Guest; Ruixue Wang; Khadija H Elkholy; Andrezza Chagas; Kinlin L Chao; Thomas E Cleveland; Young Chang Kim; Zhen-Yong Keck; Alexander Marin; Abdul S Yunus; Roy A Mariuzza; Alexander K Andrianov; Eric A Toth; Steven K H Foung; Brian G Pierce; Thomas R Fuerst
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

6.  Role of the exogenous HCV core protein in the interaction of human hepatocyte proliferation and macrophage sub-populations.

Authors:  Zhiyan Yao; Xiaotian Song; Shiru Cao; Wenzhang Liang; Wenran Lu; Lijuan Yang; Zhengzheng Zhang; Lin Wei
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

7.  HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway.

Authors:  Qianqian Zhang; Yang Wang; Naicui Zhai; Hongxiao Song; Haijun Li; Yang Yang; Tianyang Li; Xiaolin Guo; Baorong Chi; Junqi Niu; Ian Nicholas Crispe; Lishan Su; Zhengkun Tu
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

Review 8.  From Structural Studies to HCV Vaccine Design.

Authors:  Itai Yechezkel; Mansun Law; Netanel Tzarum
Journal:  Viruses       Date:  2021-05-04       Impact factor: 5.818

9.  Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience.

Authors:  Younès Cherradi; Rajaa Afifi; Hanaa Benbrahim; Wafaa Essamri; Imane Benelbarhdadi; Fatima Zahra Ajana; Hadj Omar El Malki; Mustapha Benazzouz; Abdellah Essaid
Journal:  ISRN Hepatol       Date:  2012-12-23

Review 10.  Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

Authors:  Jian Wu
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.